
Meet: Chad Geringer
Chad Geringer recently joined biomodal and focuses on business development in North America.
Chad Geringer recently joined biomodal and focuses on business development in North America.
Dr Aziz Mustafa recently joined biomodal as our Director of Sales and Business Development for Europe.
We caught up with Aziz to learn more about him, his background, and what excites him about the field of epigenetics.
Two decades ago the Human Genome Project was completed. Since then, the first sequence of the human genome and subsequent population genomes have provided critical
In a recent paper published in Cell, researchers from Harvard Medical School investigated if loss of epigenetic information was a cause of ageing. To do
In this article, we highlight three recent studies that showcase the power of methylation screening for the diagnosis and prognostic measurement of different types of
Review performance of duet multiomics solution +modC for the detection of genetic and epigenetic sequence data at base resolution when using formalin damaged DNA. Samples include formalin-compromised DNA standards (fcDNA) as well as DNA extracted from formalin-fixed and paraffin-embedded (FFPE) samples of two colorectal cancer (CRC) patients.
biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single
It all started with an epigenetic discovery Since Cambridge Epigenetix began in 2012, we’ve been innovating in the field of DNA sequencing and epigenetics. Back
Representatives from our R&D team presented 3 posters at the Advances in Genome Biology & Technology General Meeting in Hollywood, Florida.
We are extremely proud to announce that our paper ‘Simultaneous sequencing of genetic and epigenetic bases in DNA’ has been published by the journal Nature Biotechnology.